Advanced Solid Tumor Clinical Trials in Scottsdale, Arizona

9 studies are recruiting for advanced solid tumor in Scottsdale, Arizona right now. Each one is listed on ClinicalTrials.gov, the public registry the research teams themselves file with. TrialBoost is not a doctor, a research site, or a study sponsor: the research team decides who takes part.

Search these by distance from you

Studies now recruiting

1. A Study of KK2269 in Adult Participants With Solid Tumors

   This is a first-in-human study of KK2269. Part 1 and Part 2 will be conducted as a multicenter, open-label, non-randomized, dose-escalation study. Participants with advanced or metastatic solid tumors for which no standard therapy is available will be enrolled in Part 1. In Part 1, the primary obje…

   Stage

   Phase 1

   Ages

   18 and older

   Site

   Mayo Clinic Arizona, Scottsdale, Arizona

   Locations

   32 in total

   Run by

   Kyowa Kirin Co., Ltd.

   See if you can join NCT06266299 on ClinicalTrials.gov

2. SW-682 in Advanced Solid Tumors

   This is a first-in-human (FIH), Phase 1a/1b open-label, multicenter, dose escalation and dose expansion study of SW-682 in adult participants with metastatic or unresectable advanced solid tumors with or without Hippo pathway alterations that are refractory to, or have progressed, during or after a…

   Stage

   Phase 1

   Ages

   18 and older

   Site

   HonorHealth Research Institute, Scottsdale, Arizona

   Locations

   8 in total

   Run by

   SpringWorks Therapeutics, Inc., a healthcare company of Merck KGaA, Darmstadt, Germany

   See if you can join NCT06251310 on ClinicalTrials.gov

3. Phase 1/2 Study of Intravenous Injection of STX-003 in Advanced Solid Tumors as Monotherapy or in Combination With Pembrolizumab

   Phase 1/2, Open-label, Multi-center, First-in-human Study of the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics and Anti-tumor Activity of STX-003 Delivered by Intravenous Injection in Patients with Advanced Solid Tumors as a Monotherapy or in Combination with Pembrolizumab.

   Stage

   Phase 1

   Ages

   18 and older

   Site

   HonorHealth Research Institute, Scottsdale, Arizona

   Locations

   2 in total

   Run by

   Strand Therapeutics Inc.

   See if you can join NCT07751042 on ClinicalTrials.gov

4. A Study of PYX-201 in Advanced Solid Tumors

   The primary objectives of this study are to determine the recommended dose(s) of PYX-201 for participants with recurrent/metastatic (R/M) solid tumors, and to determine the objective response rate (ORR) in participants treated with PYX-201 as a single agent.

   Stage

   Phase 1

   Ages

   18 and older

   Site

   HonorHealth Research Institute, Scottsdale, Arizona

   Locations

   29 in total

   Run by

   Pyxis Oncology, Inc

   See if you can join NCT05720117 on ClinicalTrials.gov

5. First-in-Human Study of PLX-61639 in Locally Advanced or Metastatic Solid Tumors

   A multicenter, single-arm, first-in-human study to investigate the safety, pharmacokinetics, and preliminary antitumor activity of PLX-61639 in participants with locally advanced or metastatic, relapsed/refractory, SMARCA4-deficient solid tumors who are intolerant of or have failed available, appro…

   Stage

   Phase 1

   Ages

   18 and older

   Site

   Research Site, Scottsdale, Arizona

   Locations

   10 in total

   Run by

   Plexium, Inc.

   See if you can join NCT07284186 on ClinicalTrials.gov

6. A Study to Evaluate PEEL-224 in Patients With Advanced Solid Tumors

   This is a first-in-human, dose escalation, repeat-dose, multi-center, open-label study evaluating safety, tolerability, PK, and preliminary antitumor activity of PEEL-224 in patients with advanced solid tumors.

   Stage

   Phase 1

   Ages

   18 and older

   Site

   HonorHealth Research Institiute, Scottsdale, Arizona

   Locations

   8 in total

   Run by

   Peel Therapeutics Inc

   See if you can join NCT05329103 on ClinicalTrials.gov

7. A Study of CLSP-1025 in Adult Patients With Solid Tumors That Harbor the p53 R175H Mutation

   Phase 1 dose escalation and expansion study of CLSP-1025, a first-in-class HLA-A*02:01 specific T cell engager (TCE) targeting solid tumors that harbor the p53 R175H mutation.

   Stage

   Phase 1

   Ages

   18 and older

   Site

   HonorHealth Research Institute, Scottsdale, Arizona

   Locations

   21 in total

   Run by

   Clasp Therapeutics, Inc.

   See if you can join NCT06778863 on ClinicalTrials.gov

8. Phase 1/2 Study of Intratumoral Injection of STX-001 in Advanced Solid Tumors as Monotherapy or in Combination With Pembrolizumab

   Phase 1/2, Open-label, Multi-center, First-in-human Study of the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics and Anti-tumor Activity of STX-001 Delivered by Intratumoral Injection in Patients with Advanced Solid Tumors as a Monotherapy or in Combination with Pembrolizumab. The study no…

   Stage

   Phase 1

   Ages

   18 and older

   Site

   HonorHealth Research and Innovation Institute, Scottsdale, Arizona

   Locations

   7 in total

   Run by

   Strand Therapeutics Inc.

   See if you can join NCT06249048 on ClinicalTrials.gov

9. A Study to Evaluate the Safety and Therapeutic Activity of GI-102 As a Single Agent and in Combination with Conventional Anti-cancer Drugs, Pembrolizumab or Trastuzumab Deruxtecan(T-DXd) in Patients with Advanced Solid Tumors (KEYNOTE-G08)

   The purpose of this study is to evaluate the safety, tolerability, pharmacokinetics, and therapeutic activity of GI-102 as a single agent and in combination with conventional anti-cancer drugs, pembrolizumab or trastuzumab deruxtecan(T-DXd) over a range of advanced and/or metastatic solid tumors.

   Stage

   Phase 1

   Ages

   18 and older

   Site

   Mayo Clinic in Arizona, Scottsdale, Arizona

   Locations

   11 in total

   Run by

   GI Innovation, Inc.

   See if you can join NCT05824975 on ClinicalTrials.gov